Tepezza (teprotumumab) is a monoclonal antibody medication which was FDA-approved in the US in the spring of 2020. Tepezza is the only medication which has been shown to permanently improve inflammation, proptosis, and double vision in patients with thyroid eye disease.
What is Tepezza?
Patient after 2 of 8 doses of Tepezza
Who is a candidate for Tepezza?
Currently, patients who have active thyroid eye disease and meet specific clinical criteria (clinical activity score >4) are a candidate for the drug. Tepezza may work better the earlier you start the drug, so do not delay getting a formal evaluation! However, Dr. Ramesh is part of ongoing studies for patients who have chronic thyroid eye disease (meaning they have had the disease for > 2 years). Patients may still benefit from being treated even if they have had disease for years. We encourage an evaluation with Dr. Ramesh to see if Tepezza is right for you.
What are common side effects?
Tepezza is not for patients with inflammatory bowel disease (Crohn’s or ulcerative colitis). The most common side effects included high blood sugar, muscle spasm, tinnitus (ringing ears), and gastrointestinal upset. 90% of patients who start Tepezza are able to finish the treatment without having to stop due to other side effects. Dr. Ramesh is also experienced in alternate dosing regimens to minimize the risk of side effects.
Patient after 4 of 8 doses of Tepezza
Patient with reduction in periorbital fat after just 1 of 8 doses of Tepezza